Treatment of Guillain-Barré syndrome

QJM: An International Journal of Medicine

Volumn 95, Issue 11, 2002, Pages 717-721

  Winer, J B ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; STEROID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HUMAN; INTENSIVE CARE; PHYSIOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; VEIN THROMBOSIS;

EID: 0036844172     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/95.11.717     Document Type: Review

References (28)

1. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire: remarques sur les characteres clinique et graphique des reflexes tendinaux. Bull Soc Med Hop 1916; 40:1462-70.
2. Asbury AK, Arnason BG, Karp HR, McFarlin DE. Criteria for the diagnosis of Guillain-Barré syndrome. Ann Neurol 1978; 3:565-6.
3. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27:S21-4.
4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine 1969; 48:173-215.
5. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118:597-605.
6. Hughes R, Hadden R, Gregson N, Smith K. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999; 100:74-97.
7. Fisher C. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 225:57-75.
8. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43:1911-17.
9. Hughes RAC, van der Meché FGA. Corticosteroid Treatment for Guillain-Barré Syndrome (Cochrane Review). Oxford, Update Software, 1999.
10. Hughes RAC, Raphael JC, Swan AV, van Doorn PA. Intravenous Immunoglobulin for Guillain-Barré Syndrome (Cochrane Review). Oxford, Update Software, 2002.
11. Raphael JC, Chevret S, Hughes RAC. Plasma Exchange for Guillain-Barré Syndrome (Cochrane Review). Oxford, Update Software, 2001.
12. Anonymous. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome: Guillain-Barré Syndrome Steroid Trial Group. Lancet 1993; 341:586-90.
13. Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976; 26:205-12.
14. Van Koningsveld R, van der Meché FGA, Schmitz PI, Van Doorn PA. Combined therapy of intravenous immunoglobulin and methylprednisolone in patients with Guillain-Barré syndrome: the results of a multicentre double blind placebo controlled clinical trial. Peripher Nerv Syst 2001; 6:186-7.
15. Farkkila M, Kinnunen E, Haapanen E, Iivanainen M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 1987; 37:837-40.
16. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 1:877-9.
17. Anonymous. Plasmapheresis and acute Guillain-Barré syndrome: the Guillain-Barré syndrome Study Group. Neurology 1985; 35:1096-104.
18. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2:1296-9.
19. Anonymous. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol 1987; 22:753-61.
20. Anonymous. Appropriate number of plasma exchanges in Guillain-Barré syndrome: French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1997; 41:298-306.
21. Wollinsky K, Hulser P, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2001; 57:774-80.
22. Imbach P, Barundun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High dose intravenous gammaglobulin for idiopathic thrombocytopaenic purpura. Lancet 1981; 1:1228-31.
23. Vermeulin M, van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985; 70:317-26.
24. Kleyweg RP, van der Meché FGA. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiat 1991; 54:957-60.
25. van der Meché FGA, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326:1123-9.
26. Anonymous. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome: Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997; 349:225-30.
27. Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995; 27:241-3.
28. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2:750-3.